Stifel lowered the firm’s price target on Atara Biotherapeutics to $2.30 from $4.80 and keeps a Hold rating on the shares. The firm is intrigued by the partial Human Leukocyte Antigens matching approach with ATA3219 in both Lymphoma and Lupus, but are looking for more validation that efficacy will match autologous CAR T before getting constructive, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA:
- Atara Biotherapeutics Board Member Decides Not to Seek Re-Election
- Atara Biotherapeutics’ Profitability Hinges on Partners’ Success with Ebvallo Amid Market Challenges
- FDA clears Atara’s IND application in LN for allogeneic CAR T therapy ATA3219
- ATRA Upcoming Earnings Report: What to Expect?
- Atara Biotherapeutics Restructures, CMO Transitions to Consultant
